Johnson & Johnson to buy Swiss biopharma firm for $30B

Posted online January 26, 2017 | 12:33 pm

Johnson & Johnson set in motion plans to buy Swiss biopharmaceutical company Actelion Ltd. for $30 billion.

J&J officials say the deal that's expect to close in the second quarter would immediately bump up its earnings per share and revenue.

Actelion’s drugs Tracleer, Opsumit and Uptravi all treat life-threatening pulmonary arterial hypertension.

Read more from USA Today.

[[In-content Ad]]

Comments

No comments on this story |

Please log in to add your comment

Noodle shop opens on south side

Editors' Pick

Open for Business: Show Me Chuy

April 7 was the official opening day for Mexican-Italian fusion restaurant Show Me Chuy after a soft launch that started March 31; marketing agency AdZen debuted; and the Almighty Sando Shop opened a brick-and-mortar space.

Most Read